GLUD1 and familial pancreatic carcinoma: reported that in pancreatic cancer, oncogenic KRAS regulates glutamine metabolic reprogramming by transcriptionally upregulating aspartate aminotransferase (AST) expression and inhibiting glutamate dehydrogenase 1 (GLUD1) (67).